{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:34:37Z","timestamp":1793237677503,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014434","name":"Columbia University Irving Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003718","name":"Korea Institute of Oriental Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020066","name":"Feldstein Medical Foundation Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020066","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jacadv.2026.102956","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:42:21Z","timestamp":1782920541000},"page":"102956","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Experience With Mavacamten in SRT-Eligible Obstructive HCM"],"prefix":"10.1016","volume":"5","author":[{"given":"Lusha W.","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroo","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamim M.","family":"Nazif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Gojcaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi J.","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shepard D.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacadv.2026.102956_bib1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/01.CIR.92.4.785","article-title":"Prevalence of hypertrophic cardiomyopathy in a general population of young adults","volume":"92","author":"Maron","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.102956_bib2","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jacc.2021.11.021","article-title":"Management of hypertrophic Cardiomyopathy","volume":"79","author":"Maron","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.102956_bib3","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.102956_bib4","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(16)31321-6","article-title":"Hypertrophic obstructive cardiomyopathy","volume":"389","author":"Veselka","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacadv.2026.102956_bib5","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical course and management of hypertrophic cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.102956_bib6","first-page":"558","article-title":"2020 AHA\/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy","volume":"142","author":"Ommen","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.102956_bib7","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.cardfail.2024.04.024","article-title":"Evolving strategies for the management of obstructive hypertrophic cardiomyopathy","volume":"30","author":"Liang","year":"2024","journal-title":"J Card Fail"},{"issue":"23","key":"10.1016\/j.jacadv.2026.102956_bib8","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.jacc.2024.02.014","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR Guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Ommen","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.102956_bib9","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jtcvs.2018.08.062","article-title":"Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy: a propensity score\u2013matched cohort","volume":"157","author":"Nguyen","year":"2019","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jacadv.2026.102956_bib10","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jacadv.2026.102956_bib11","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.102956_bib12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.102956_bib13","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/jamacardio.2023.3342","article-title":"Mavacamten in patients with hypertrophic Cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial","volume":"8","author":"Desai","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacadv.2026.102956_bib14","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1161\/CIRCULATIONAHA.124.072445","article-title":"Mavacamten in patients with hypertrophic Cardiomyopathy referred for septal reduction: week 128 results from VALOR-HCM","volume":"151","author":"Desai","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.102956_bib15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jchf.2017.09.011","article-title":"Clinical spectrum and management of heart failure in hypertrophic cardiomyopathy","volume":"6","author":"Maron","year":"2018","journal-title":"JACC Hear Fail"},{"key":"10.1016\/j.jacadv.2026.102956_bib16","article-title":"Incidence and recurrence of atrial fibrillation among patients with obstructive hypertrophic cardiomyopathy treated with mavacamten: a single-center experience","author":"Liang","year":"2024","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.jacadv.2026.102956_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.hrthm.2024.04.055","article-title":"Incidence of newly recognized atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy treated with Mavacamten","author":"Castrichini","year":"2024","journal-title":"Hear Rhythm"},{"key":"10.1016\/j.jacadv.2026.102956_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacep.2024.10.014","article-title":"Atrial fibrillation in patients receiving mavacamten for obstructive hypertrophic cardiomyopathy: real-world incidence, management, and outcomes","author":"Boyle","year":"2025","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.jacadv.2026.102956_bib19","article-title":"Incidence and outcomes of atrial fibrillation and systolic dysfunction in patients receiving mavacamten for obstructive hypertrophic cardiomyopathy: a multicenter study","author":"Nguyen","year":"2025","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacadv.2026.102956_bib20","article-title":"Mavacamten: real-world experience from 22 months of the risk Evaluation and Mitigation Strategy Program","volume":"18","author":"Desai","year":"2025","journal-title":"Circ Hear Fail"},{"key":"10.1016\/j.jacadv.2026.102956_bib21","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/j.jacc.2021.09.1381","article-title":"Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Hegde","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.102956_bib22","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.122.014986","article-title":"Myosin inhibition and left ventricular diastolic function in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy: insights from the VALOR-HCM Study","volume":"15","author":"Cremer","year":"2022","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacadv.2026.102956_bib23","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.jcmg.2023.06.008","article-title":"Early observations on effects of mavacamten on left atrial function in obstructive hypertrophic cardiomyopathy patients","volume":"16","author":"Wessly","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacadv.2026.102956_bib24","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/CIRCULATIONAHA.120.052359","article-title":"Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy","volume":"143","author":"Saberi","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.102956_bib25","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.hlc.2017.05.116","article-title":"Atrial fibrillation in hypertrophic cardiomyopathy","volume":"26","author":"Vaidya","year":"2017","journal-title":"Hear Lung Circ"},{"key":"10.1016\/j.jacadv.2026.102956_bib26","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1093\/eurheartj\/ehad637","article-title":"Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy","volume":"44","author":"Braunwald","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2026.102956_bib27","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.jacc.2015.06.1333","article-title":"Low operative mortality achieved with surgical septal myectomy: role of dedicated hypertrophic cardiomyopathy centers in the management of dynamic subaortic obstruction","volume":"66","author":"Maron","year":"2015","journal-title":"JACC"},{"key":"10.1016\/j.jacadv.2026.102956_bib28","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2005.02.090","article-title":"Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy","volume":"46","author":"Ommen","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.102956_bib29","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.amjcard.2022.05.032","article-title":"Ventricular septal myectomy decreases long-term risk for atrial fibrillation in patients with hypertrophic cardiomyopathy","volume":"179","author":"Rowin","year":"2022","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacadv.2026.102956_bib30","first-page":"369","article-title":"Mavacamten for hypertrophic cardiomyopathy: effectiveness and value","volume":"28","author":"Beinfeld","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"10.1016\/j.jacadv.2026.102956_bib31","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.athoracsur.2022.05.062","article-title":"Impact of hospital volume on outcomes of septal myectomy for hypertrophic cardiomyopathy","volume":"114","author":"Holst","year":"2022","journal-title":"Ann Thorac Surg"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26003777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26003777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:25:41Z","timestamp":1793237141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X26003777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2772963X26003777"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.102956","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Experience With Mavacamten in SRT-Eligible Obstructive HCM","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.102956","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"102956"}}